Biomea Fusion Inc. ( BMEA) reported Phase 1 results for BMF-650, its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed for obesity and metabolic disorders. The ...
Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced ...
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe ...
Biomea Fusion, Inc. (?Biomea? or the ?Company?) announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist (?GLP-1 ...
Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that the first patient has been dosed in ...
Third drug candidate from Tenvie’s product engine to enter clinical development in 2026; TNV313 joins TNV262 to give Tenvie ...
Palisade Bio, Inc. announced clinical and translational findings featured in five poster presentations at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, ...
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical ...
A first-in-human trial shows that the conformation-selective PI3Kδ inhibitor roginolisib is well tolerated in advanced ...
New clinical data at the HFSA ASM 2026 showcases the pharmacokinetic and pharmacodynamic performance of Furoscix ReadyFlow, ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results